Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pacific Edge Limited ( (PFGTF) ) has shared an update.
Cancer diagnostics firm Pacific Edge has secured the first order for its Cxbladder Triage Plus test from Townsville University Hospital, following an initial wave of patient referrals in North Queensland. The hospital’s consultant urologists have created nurse-led protocols that incorporate Triage Plus for hematuria evaluation and Cxbladder Monitor for non-muscle invasive bladder cancer surveillance, aiming to streamline care for a catchment of about 700,000 people.
Under the new clinical pathway, Triage Plus will help stratify hematuria patients by bladder cancer risk, allowing clinicians to reduce invasive procedures for low-risk cases while prioritizing high-risk patients for immediate attention. Cxbladder Monitor will support safer reductions in cystoscopy frequency for surveillance patients, with recent real-world studies in Australia showing cost savings, higher patient satisfaction, and operational efficiencies.
Triage Plus, a multi-modal RNA and DNA urine test, has demonstrated superior performance over earlier Cxbladder generations and carries strong clinical validation, including evidence recognized in leading urology guidelines. The shift toward nurse-led implementation is expected to improve health economic outcomes and enhance Pacific Edge’s margins per test, reinforcing the company’s growing footprint in Australia and complementing its broader global adoption across the U.S., Australasia, Israel, and select Asian and South American markets.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of non-invasive genomic urine tests for bladder cancer diagnosis and surveillance. Headquartered in Dunedin, New Zealand, it offers its Cxbladder test suite through CLIA-certified laboratories in New Zealand and the United States, targeting patients with hematuria and those monitored for recurrent urothelial disease.
For detailed information about PFGTF stock, go to TipRanks’ Stock Analysis page.